327 related articles for article (PubMed ID: 27576731)
21. MEDI-573, alone or in combination with mammalian target of rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas.
Zhong H; Fazenbaker C; Breen S; Chen C; Huang J; Morehouse C; Yao Y; Hollingsworth RE
Mol Cancer Ther; 2014 Nov; 13(11):2662-73. PubMed ID: 25193511
[TBL] [Abstract][Full Text] [Related]
22. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
23. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
Guenther LM; Dharia NV; Ross L; Conway A; Robichaud AL; Catlett JL; Wechsler CS; Frank ES; Goodale A; Church AJ; Tseng YY; Guha R; McKnight CG; Janeway KA; Boehm JS; Mora J; Davis MI; Alexe G; Piccioni F; Stegmaier K
Clin Cancer Res; 2019 Feb; 25(4):1343-1357. PubMed ID: 30397176
[TBL] [Abstract][Full Text] [Related]
24. Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma.
Santoro M; Lamhamedi-Cherradi SE; Menegaz BA; Ludwig JA; Mikos AG
Proc Natl Acad Sci U S A; 2015 Aug; 112(33):10304-9. PubMed ID: 26240353
[TBL] [Abstract][Full Text] [Related]
25. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
[TBL] [Abstract][Full Text] [Related]
26. Cotargeting BET proteins overcomes resistance arising from PI3K/mTOR blockade-induced protumorigenic senescence in colorectal cancer.
Lee HS; Lee S; Cho KH
Int J Cancer; 2020 Nov; 147(10):2824-2837. PubMed ID: 32599680
[TBL] [Abstract][Full Text] [Related]
27. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
[TBL] [Abstract][Full Text] [Related]
28. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
29. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
30. Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma.
Shackleford TJ; Hariharan S; Vaseva AV; Alagoa K; Espinoza M; Bid HK; Li F; Zhong H; Phelps DA; Roberts RD; Cam H; London CA; Guttridge DC; Chen Y; Rao M; Shiio Y; Houghton PJ
Mol Cancer Ther; 2023 Apr; 22(4):539-550. PubMed ID: 36696581
[TBL] [Abstract][Full Text] [Related]
31. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
32. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
34. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
[TBL] [Abstract][Full Text] [Related]
35. Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells.
Bianchini A; Loiarro M; Bielli P; Busà R; Paronetto MP; Loreni F; Geremia R; Sette C
Carcinogenesis; 2008 Dec; 29(12):2279-88. PubMed ID: 18809972
[TBL] [Abstract][Full Text] [Related]
36. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
Kuhn DJ; Berkova Z; Jones RJ; Woessner R; Bjorklund CC; Ma W; Davis RE; Lin P; Wang H; Madden TL; Wei C; Baladandayuthapani V; Wang M; Thomas SK; Shah JJ; Weber DM; Orlowski RZ
Blood; 2012 Oct; 120(16):3260-70. PubMed ID: 22932796
[TBL] [Abstract][Full Text] [Related]
37. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
[TBL] [Abstract][Full Text] [Related]
39. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Murakami T; Singh AS; Kiyuna T; Dry SM; Li Y; James AW; Igarashi K; Kawaguchi K; DeLong JC; Zhang Y; Hiroshima Y; Russell T; Eckardt MA; Yanagawa J; Federman N; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
Oncotarget; 2016 Jul; 7(30):47556-47564. PubMed ID: 27286459
[TBL] [Abstract][Full Text] [Related]
40. ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer.
Zinn RL; Gardner EE; Marchionni L; Murphy SC; Dobromilskaya I; Hann CL; Rudin CM
Mol Cancer Ther; 2013 Jun; 12(6):1131-9. PubMed ID: 23515613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
